At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company") wishes to confirm that the Company's management is ...

Quantum BioPharma invented unbuzzd and spun out its OTC version to a company, Celly Nutrition Corp. ("Celly Nutrition"), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as ...

Quantum BioPharma Ltd. has successfully completed its Phase 1 clinical trial of Lucid-21-302, also known as Lucid-MS, a novel compound aimed at treating multiple sclerosis (MS). A safety review ...

Safety Review Committee Found No Safety Concerns Following Milestone Trial TORONTO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum ...

Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), led by industry veterans. Quantum BioPharma retains ownership of 25.71% (as of ...

Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and HangoverTORONTO, Feb. 04, ...

The company also has a stake in Celly Nutrition Corp., which markets an over-the-counter product, unbuzzd™, and retains the rights to develop pharmaceutical and medical applications of similar ...

其主打化合物Lucid-MS旨在预防和逆转多发性硬化症中的髓鞘退化。公司还持有Celly Nutrition Corp.的股份，后者销售非处方产品unbuzzd™，并保留开发类似产品的制药和医疗应用权。 公司对加密货币的投资反映了其对数字资产潜力的信心，以及通过子公司FSD Strategic ...